Two recent phase II trials examined the efficacy of abiraterone acetate, a CYP17 inhibitor that impairs androgen synthesis, in patients with castration resistant prostate cancer used CTCs as efficacy markers. Here, CYP17A1 is linked to prostate carcinoma.